Summary
This filing is an amendment to Vertex Pharmaceuticals Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2008. The amendment's primary purpose is to refile an exhibit with fewer redactions, for which the company had previously requested confidential treatment. Importantly, this amendment does not update the financial or operational disclosures beyond the original filing date of August 11, 2008. Therefore, the information presented reflects the company's status and financial position as of that earlier date, not as of September 7, 2012, when this amendment was filed. Investors reviewing this document should be aware that it is not a current report on the company's performance in 2012. It serves as a historical record and an update to a specific exhibit from a filing made over four years prior to the current filing date. For up-to-date financial and operational information, investors should consult Vertex Pharmaceuticals' more recent filings.
Key Highlights
- 1This filing is an amendment (10-Q/A) to the Quarterly Report for the period ended June 30, 2008.
- 2The amendment's primary purpose is to refile a previously submitted exhibit with reduced redactions.
- 3The company had requested confidential treatment for this exhibit.
- 4This amendment does not update disclosures to reflect events occurring after the original filing date of August 11, 2008.
- 5The filing reaffirms Vertex Pharmaceuticals' status as a large accelerated filer.
- 6As of August 6, 2008, 141,529,503 shares of common stock were outstanding.
- 7The filing includes new officer certifications as required by Rule 13a-14(a).